137 related articles for article (PubMed ID: 36128258)
1. MicroRNAs as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing?
Gramantieri L; Fornari F
Oncoscience; 2022; 9():52-54. PubMed ID: 36128258
[No Abstract] [Full Text] [Related]
2. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.
Tian Y; Lei Y; Fu Y; Sun H; Wang J; Xia F
Curr Cancer Drug Targets; 2022; 22(6):454-462. PubMed ID: 35362393
[TBL] [Abstract][Full Text] [Related]
3. Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors.
Maeda H; Miura K; Morimoto N; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Goka R; Sato N; Morishima K; Sakuma Y; Sata N; Fukushima N; Isoda N; Yamamoto H
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159018
[TBL] [Abstract][Full Text] [Related]
4. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma.
Zhang C; Xia R; Zhang B; Wang H
BMC Cancer; 2018 Nov; 18(1):1110. PubMed ID: 30424721
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.
Roderburg C; Özdirik B; Wree A; Demir M; Tacke F
Hepat Oncol; 2020 May; 7(2):HEP20. PubMed ID: 32647565
[TBL] [Abstract][Full Text] [Related]
6. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
[TBL] [Abstract][Full Text] [Related]
7. Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma.
Nawa T; Katayama K; Kiyota R; Imai T; Abe Y; Hasegawa N; Takada R; Fukutake N; Ikezawa K; Sakakibara M; Fujita M; Ohkawa K
Clin J Gastroenterol; 2020 Apr; 13(2):247-251. PubMed ID: 31317371
[TBL] [Abstract][Full Text] [Related]
8. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs in the Occurrence and Development of Primary Hepatocellular Carcinoma.
Xu J; Li J; Zheng TH; Bai L; Liu ZJ
Adv Clin Exp Med; 2016; 25(5):971-975. PubMed ID: 28028963
[TBL] [Abstract][Full Text] [Related]
10. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Wu Y; Xu X
Life Sci; 2021 Jan; 265():118799. PubMed ID: 33220285
[TBL] [Abstract][Full Text] [Related]
11. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Efficacy of Serum Exosomal microRNA-122 and microRNA-148a for Hepatocellular Carcinoma Based on Smart Healthcare.
Deng P; Li M; Wu Y
J Healthc Eng; 2022; 2022():5914541. PubMed ID: 35028121
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas.
Anwar SL; Lehmann U
J Clin Med; 2015 Aug; 4(8):1631-50. PubMed ID: 26295264
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic potential of serum microRNA-4651 for patients with hepatocellular carcinoma related to aflatoxin B1.
Wu XM; Xi ZF; Liao P; Huang HD; Huang XY; Wang C; Ma Y; Xia Q; Yao JG; Long XD
Oncotarget; 2017 Oct; 8(46):81235-81249. PubMed ID: 29113383
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Circulating microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Jin X; Cai C; Qiu Y
J Cancer; 2019; 10(20):4754-4764. PubMed ID: 31598147
[TBL] [Abstract][Full Text] [Related]
16. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.
Lee SW; Yang SS; Lien HC; Peng YC; Tung CF; Lee TY
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013120
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Jindal A; Thadi A; Shailubhai K
J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
[TBL] [Abstract][Full Text] [Related]
18. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
da Fonseca LG; Reig M; Bruix J
Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
[TBL] [Abstract][Full Text] [Related]
20. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
de Rosamel L; Blanc JF
Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
